People's Liberation Army General Hospital of Chengdu Military Region
Chengdu, China
NCT Number: NCT02815722
The purpose of the study is to investigate the potential interaction between SP2086 and Simvastatin after the multiple oral doses treatment in healthy adult volunteers.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Chengdu, China
This is an open-label (volunteers will know the names of treatments they are assigned) single-center and cross-over study of SP2086 and Simvastatin in healthy adult volunteers. All subject were randomized into two groups, and the drugs will be administered according to the AB and BA sequences. The A sequence was that SP2086 was taken at 40mg qd on Day1-Day 10; Simvastatin will be administered orally (by mouth) as 200mg on Day 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd on Day6-Day10. There were 5 days washout period between A and B. The total time of this trial was 27 days.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
Time frame: up to Day 27
Cmax (a measure of the body's exposure to SP2086) will be compared before and after administration of multiple doses of SP2086
Time frame: up to Day 27
Cmax (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of multiple doses of SP2086
Time frame: up to Day 27
Cmax (a measure of the body's exposure to Simvastatin) will be compared before and after administration of multiple doses of Simvastatin
Time frame: up to Day 27
AUC (a measure of the body's exposure to SP2086) will be compared before and after administration of multiple doses of SP2086
Time frame: up to Day 27
AUC (a measure of the body's exposure to SP2086 acid) will be compared before and after administration of multiple doses of SP2086
Time frame: up to Day 27
AUC (a measure of the body's exposure to Simvastatin) will be compared before and after administration of multiple doses of Simvastatin
Time frame: up to Day 27
Jiangsu HengRui Medicine Co., Ltd.
Industry
A Single Randomized, Open,Cross-over, Phase Ig Study to Access the Drug-drug Interaction of SP2086 and Simvastatin
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05929079
Apnea, Body Weight
Anniston, Alabama, United States
View Trial DetailsNCT06649344
Diabetes Mellitus, Diabetes Mellitus, Type 2
Tianjin, Tianjin Municipality, China
View Trial DetailsNCT07732218
Diabetes Mellitus, Diabetes Mellitus, Type 2
Peshawar, Khyber Pakhtunkhwa, Pakistan
View Trial DetailsNCT05351359
Diabetes Mellitus, Diabetes Mellitus, Type 2
Prague, Czechia
View Trial Details